Do patients with urodynamically proven infravesical obstruction and detrusor overactivity have a higher risk for long-term bothersome symptoms after brachytherapy in comparison to patients treated with radical prostatectomy for localized prostate cancer?

Current Urology

Volumn 2, Issue 3, 2009, Pages 135-141

  Kirschner Hermanns, Ruth ^a   Brehmer, Bernhard ^a   Borchers, Holger ^a   Kahle, Christina ^a   Eble, Michael J ^a   Reineke, Thorsten ^a   Jakse, Gerhard ^a   Pinkawa, Michael ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Brachytherapy; Prostate cancer; Prostatectomy; Urinary incontinence; Urodynamic

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BLADDER OBSTRUCTION; BRACHYTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; URINARY URGENCY; URODYNAMICS;

EID: 77953453902     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000189654     Document Type: Article

References (34)

1. D'Amico AV, Vogelzang NJ: Prostate brachytherapy: increasing demand for the procedure despite the lack of standardized quality assurance and long term outcome data. Cancer 1999;86:1632-1634.
2. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH: Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19:1619-1628.
3. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.
4. Mallick S, Azzouzi R, Cormier L, Peiffert D, Mangin PH: Urinary morbidity after 125I brachytherapy of the prostate. BJU Int 2003;92:555-558.
5. Wagner TT, Nag S, Young D, Bahnson RR: Early voiding dysfunction associated with prostate brachytherapy. Urol Oncol 2000;6:20-23.
6. Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS, Carroll PR, Lubeck DP: Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer - data from CaPSURE. J Urol 2003;170:1822-1827.
7. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL: A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:614-623.
8. Nag S, Beyer D, Friedland J, Grimm P, Nath R: American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-799.
9. Krupski T, Petroni GR, Bissonette EA, Theodorescu D: Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Prostate Cancer Prostatic Dis 1999;2(suppl):32.
10. Brandeis JM, Litwin MS, Burnison CM, Reiter RE: Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000;163:851-857.
11. Al-Booz H, Ash D, Bottomley DM, Carey BM: Short-term morbidity and acceptability of 125iodine implantation for localized carcinoma of the prostate. BJU Int 1999;83:53-56.
12. Weldon VE, Tavel FR, Neuwirth H: Continence, potency and morbidity after radical perineal prostatectomy. J Urol 1997;158:1470-1475.
13. Jakse G, Manegold E, Reineke T, Borchers H, Brehmer B, Wolff JM, Mittermayer C: Expanded, radical perineal prostatectomy. Urologe A 2000;39:455-462.
14. Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P: Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261-274.
15. Schafer,W: Principles and clinical application of advanced urodynamic analysis of voiding function. Urol Clin North Am 1990;17:553-566.
16. Schafer W: Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: from complex to simple. World J Urol 1995;13:47-58.
17. Crook J, Toi A, McLean M, Pond G: The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. Brachytherapy 2002;1:131-137.
18. Crook JM, Potters L, Stock RG, Zelefsky MJ: Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy 2005;4:186-194.
19. Pedley ID: Transperineal interstitial permanent prostate brachytherapy for carcinoma of the prostate. Surg Oncol 2002;11:25-34.
20. Pinkawa M, Maurer U, Mulhern A, Gagel B, Block T, Borchers H, Grieger J, Henkel T, Eble MJ: Inverse treatment planning in interstitial permanent prostate brachytherapy with 125I of different activities. Strahlenther & Onkol 2003;179:417-422.
21. Narayana V, Troyer S, Evans V, Winfield RJ, Roberson PL, McLaughlin PW: Randomized trial of high- and low-source strength (125)I prostate seed implants. Int J Radiat Oncol Biol Phys 2005;61:44-51.
22. Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E: Androgen deprivation-inducted changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2004;59:1367-1382.
23. Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA: Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517-522.
24. Saibishkumar EP, Borg J, Yeung I, Cummins-Holder C, Landon A, Crook JM: Loose seeds vs. stranded seeds: A comparison of critical organ dosimetry and acute toxicity in 125I permanent implant for low-risk proatate cancer. Brachytherapy 2008;7:200-205.
25. Henderson A, Ismail AK, Cunningham M, Aldridge S, Loverock L, Langley SE, Laing RW: Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 2004;16:95-104.
26. Coyne KS, Zhou Z, Thompson C, Versi E: The impact on health related quality of stress, urge and mixed urinary incontinence. BJU Int 2003;92:731-735.
27. Scarpa RM: Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 2001;40(suppl):12-20.
28. Merrick GS, Butler WM, Wallner KE, Allen ZA, Lief JH, Hinerman-Mulroy A, Galbreath RW: The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy. Cancer J 2004;10:181-189.
29. Merrick GS, Butler WM, Lief JH, Dorsey AT: Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121-128.
30. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH: Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 56:454-461.
31. Stone NN, Stock RG: Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 2000;46:1199-1204.
32. Sherertz T, Wallner K, Wang H, Sutlief S, Russell K: Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys 2001;51:1241-1245.
33. Abrams P: Objective evaluation of bladder outlet obstruction. Br J Urol 1995;76(suppl): 11-15.
34. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wennberg J: Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology 1995;45:1007-1013.